Core Viewpoint - Hendi Pharmaceutical (301211.SZ) announced plans for significant share reductions by major shareholders, indicating potential changes in ownership structure and market sentiment towards the company [1] Group 1: Shareholder Reductions - Jingmen Ningkang Enterprise Management Center (Limited Partnership), holding 23,490,000 shares (5.63% of total shares), plans to reduce its holdings by up to 4,176,000 shares (1% of total shares) within three months after the announcement [1] - Jingmen Beikang Enterprise Management Center (Limited Partnership), holding 7,830,000 shares (1.88% of total shares), intends to reduce its holdings by up to 1,392,000 shares (0.33% of total shares) within three months after the announcement [1] - Lei Xiaoyan, holding 15,660,000 shares (3.75% of total shares), plans to reduce her holdings by up to 4,176,000 shares (1% of total shares) within three months after three trading days from the announcement [1]
亨迪药业(301211.SZ)：宁康企管拟减持不超过1%股份